Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025

Halle (Saale) / Munich, Germany, June 11, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical-stage company focused on developing small molecule drugs for inflammatory and fibrotic conditions, particularly kidney diseases, announced today that its financial results for the first quarter ending March 31, 2025, along with a corporate update, will be released on Tuesday, June 17, 2025. The company will host a publicly accessible conference call and webcast.

Conference call details
Date: June 17, 2025
Time: 3:00 pm CEST / 9:00 am EDT

The conference call can be accessed by phone and webcast.
A live audio webcast of the call will be available on Vivoryon’s website:

To join the conference call by phone, participants can pre-register to receive dial-in details for easy and quick access via the following website:

It is recommended that participants dial into the conference call 15 minutes before the scheduled start to avoid any delays.

###

About Vivoryon Therapeutics N.V.
Vivoryon is a clinical-stage biotech company dedicated to creating innovative small molecule-based treatments for inflammatory and fibrotic kidney disorders. Driven by a commitment to pioneering science and innovation, the company aims to improve patient outcomes by altering the progression of serious diseases through modulation of the activity and stability of disease-relevant proteins. Vivoryon’s lead program, varoglutamstat, a unique, orally available QPCT/L inhibitor, is currently under evaluation for the treatment of diabetic kidney disease. 

Vivoryon Forward Looking Statements
This press release contains forward-looking statements regarding Vivoryon Therapeutics N.V. (the “Company”), including, but not limited to, its business strategy, management plans, future operational objectives, market estimates for the Company’s products, forecasts, and statements regarding product availability timelines. Terms like “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should,” and “will,” and similar expressions, are used to identify these forward-looking statements. These statements do not guarantee future performance; they reflect Management’s current expectations and assumptions about future events, trends, the economy, and other conditions. Forward-looking statements involve known and unknown risks and uncertainties that could significantly affect the outcome and financial impact of the described plans and events. The Company’s operational results, cash needs, financial status, liquidity, prospects, future transactions, strategies, or events may differ materially from those expressed or implied in these statements and from expectations. Therefore, undue reliance should not be placed on these forward-looking statements. This press release does not list all risk factors. Certain risk factors that could impact the Company’s future financial performance are discussed in the Company’s published annual financial statements. This press release, including all forward-looking statements, is current as of its date. The Company undertakes no obligation to update any information or forward-looking statements, except as required by law.

For more information, please contact:

Investor Contacts
Vivoryon Therapeutics N.V.
Dr. Manuela Bader, Director IR & Communication
Email:

LifeSci Advisors
Sandya von der Weid
Tel: +41 78 680 05 38
Email:

Media Contact
Trophic Communications
Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email:

Attachment

“`